Biogen Inc. (BIIB)

304.53
NASDAQ : Health Technology
Prev Close 304.46
Day Low/High 300.80 / 305.03
52 Wk Low/High 215.78 / 374.99
Avg Volume 2.03M
Exchange NASDAQ
Shares Outstanding 163.19M
Market Cap 49.68B
EPS 31.50
P/E Ratio 9.41
Div & Yield N.A. (N.A)
Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Biogen Could Suffer Near Term as the Chart Picture Erodes

Biogen Could Suffer Near Term as the Chart Picture Erodes

With weak chart patterns and a quantitative downgrade, longs should protect their positions.

Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval

Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval

The U.S. Food and Drug Administration approved the biotech company's treatment for spinal muscular atrophy late Friday.

My Top Pick for 2017: Short QQQ

My Top Pick for 2017: Short QQQ

Six reasons why the Nasdaq 100 ETF seems ready to pull back.

My Top Pick for 2017: Short QQQ

My trade of the year for 2017 is to short the PowerShares QQQ Trust ETF , which tracks the Nasdaq 100 index. Here's my investment thesis for this play: The Nasdaq 100 Already Has Rallied QQQ already has risen from about $96 a share at the market's F...

Sellers Are Dominating the Price Action in Biogen

Sellers Are Dominating the Price Action in Biogen

Shoppers may want to wait until after the holidays for a bargain on BIIB.

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

The bullish side dominates, with consumer cyclicals and energy names most prevalent.

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Midday Report: Stocks Higher As Wall Street Shrugs Off Trump's Presidential Election

Midday Report: Stocks Higher As Wall Street Shrugs Off Trump's Presidential Election

U.S. stocks rallied slightly in midday trading as energy, financials, and healthcare sectors saw green on Wednesday following the surprise election of Republican Donald Trump.

Biogen Sees Positive Drug Study Results

Biogen Sees Positive Drug Study Results

Shares of Biogen were higher on Monday after the biotech company and Ionis Pharmaceuticals said their Phase 3 trial of its spinal muscular atrophy drug met its primary endpoint.

Biogen upgraded at Piper

Midday Report: Apple Rallies for Day Two; U.S. Stocks Climb After Extreme Three Days

Midday Report: Apple Rallies for Day Two; U.S. Stocks Climb After Extreme Three Days

U.S. stocks bounced around in the green in far more stable trading following three days of extreme swings.

Biotech May Be About to Rescusitate

Biotech May Be About to Rescusitate

Check out this biotech ETF, and Biogen, for plays on any recovery.

Biogen downgraded at Jefferies

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Bret Jensen Reporting for Duty

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...

It's Time to Go Short Stocks; Here Are Some Ideas

It's Time to Go Short Stocks; Here Are Some Ideas

Besides Tesla, Twitter and Biogen make good candidates.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Endo International Shares Climb on Earnings Beat

Endo International Shares Climb on Earnings Beat

Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.

Watch Gilead for Buying Opportunities

Watch Gilead for Buying Opportunities

There is a case for a low already being in place.

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Biogen Tie-Up Would Still Bring Premium, Analysts Say

Deal rumors are deflating, but a takeover bid could reward holdouts.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Cramer: Does It Have to Be All About Oil?

Cramer: Does It Have to Be All About Oil?

That's a shaky basis for a rally.

Closing Bell: Biogen Spikes on Takeover Talk; Crude Closes Near Four-Month Low

Closing Bell: Biogen Spikes on Takeover Talk; Crude Closes Near Four-Month Low

U.S. stocks hold near lows through to the end of the session as crude oil closes below $40 a barrel, its lowest level since April, on continued supply worries.

Biogen Spikes as Allergan Tie-Up Rumors Flare Up Again

Biogen Spikes as Allergan Tie-Up Rumors Flare Up Again

The companies were also the subject of merger rumors back in April.